干扰素治疗复发缓解型多发性硬化的有效性研究  

Study on the Efficacy of Interferon in the Treatment of Multiple Sclerosis

作　　者：吴保凡[1] 

机构地区：[1]山东省菏泽市立医院,山东菏泽274031

出　　处：《中外医疗》2016年第31期126-128,共3页China & Foreign Medical Treatment

摘　　要：目的对复发缓解型多发性硬化治疗中干扰素的有效性进行分析探讨。方法方便选取于该院治疗复发缓解型多发性硬化的病患120例,将其作为研究对象并随机均等分为实验组和对照组,每组各60例。对对照组使用地塞米松进行治疗,实验组则在此基础上使用干扰素β进行治疗。对两组病患治疗前、治疗3个月之后、治疗6个月之后的ADL(日常生活活动量表)及NDS(神经功能缺损程度)进行评分并比对。结果经治疗6个月后,实验组ADL评分(60.52±10.47)分显著高于对照组(51.64±10.71)分,NDS评分(12.29±2.43)分显著低于对照组(15.31±3.98)分,P<0.05,差异具有统计学意义。结论对复发型多发性硬化病患使用β干扰素进行治疗能够有效改善病患的神经功能,使病患的复发概率显著下降。Objective To analyze the efficacy of interferon in the treatment of recurrent and multiple sclerosis.Methods Convenient selection from August 2015 to July 2016, 120 cases of patients with multiple sclerosis in our hospital were selected as the study subjects and randomly divided into experimental group and control group, 60 cases in each group. The control group was treated with dexamethasone, and the experimental group was treated with interferon beta. The two groups of patients before treatment, 3 months after treatment, 6 months after the treatment of ADL（daily living activity scale） and NDS（nerve function defect degree） were scored and compared. Results After 6 months of treatment, the experimental group ADL score（60.52 ±10.47）points was significantly higher than that of the control group（51.64 ± 10.71）points, NDS（12.29 ±243） points was significantly lower than that of the control group（15.31 ± 3.98）points, P〈0.05, the data can be statistically significant. Conclusion It is effective to improve the neurological function of patients with multiple sclerosis by using beta interferon, which can significantly decrease the recurrence rate of patients with multiple sclerosis.

关 键 词：干扰素 复发缓解型 多发性硬化 

分 类 号：R744.51[医药卫生—神经病学与精神病学]